ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Public perceptions of AI-assisted cancer care in Abu Dhabi, UAE: A cross-sectional survey.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is increasingly being used in oncology to support early diagnosis and develop personalized treatment plans. However, its successful use in cancer care depends not only on the technology itself, but also on whether people trust it, understand it, and are open to accepting it. This study explored how digitally engaged adults living in Abu Dhabi, UAE, perceive AI-assisted cancer treatment, focusing on how factors like demographics, AI familiarity, and personal cancer experience influence acceptance and concern. A cross-sectional survey was completed by 413 adults using a structured, bilingual (Arabic-English) questionnaire. Participants were asked about their awareness of AI in healthcare, their willingness to accept AI-assisted cancer treatment, and their concerns about issues such as safety, accuracy, cost, and data privacy. Chi-square tests were used to analyze the relationships between these factors. Familiarity with AI had a significant impact on acceptance (p = 0.0006), with those who were very familiar with AI more likely to accept its use in cancer treatment. In contrast, education level (p = 0.664) and personal experience with cancer (p = 0.3562) were not significantly associated with acceptance. Participants who were less familiar with AI expressed more concerns about its accuracy, safety, cost, and the privacy of their data (p = 0.0073), pointing to awareness as a key factor in shaping trust. These findings suggest that trust in AI-assisted cancer care is driven more by how familiar people are with the technology than by their educational background or cancer experience. To build public trust and encourage responsible use of AI in oncology, it is essential to keep healthcare professionals actively involved and to communicate clearly and transparently with patients.
Indexed as
Identifiers
41636906What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.